MILLER RICHARD A MD 4

What Happened

• Richard A. Miller, MD — President, CEO and Director of Corvus Pharmaceuticals (CRVS) — made two open-market purchases on May 18, 2026, acquiring a total of 6,932 shares. He bought 5,000 shares at $12.05 each ($60,250) and 1,932 shares at $12.01 each ($23,203), for a combined cash outlay of approximately $83,453. These were purchases (transaction code P), which investors often view as more informative than routine sales.

Key Details

• Transaction dates and prices: May 18, 2026 — 5,000 shares @ $12.05; May 18, 2026 — 1,932 shares @ $12.01.
• Total shares purchased: 6,932; total value: ~$83,453.
• Shares owned after transaction: Not specified in the excerpt of this filing.
• Footnote: Shares are held by the Miller-Horning Family Trust dated January 25, 1985; Dr. Miller and Sandra J. Horning are trustees. Dr. Miller has shared voting, investment and dispositive power over those trust-held shares (see F1).
• Filing timeliness: Form 4 was filed on May 20, 2026, covering transactions on May 18, 2026 — appearing to be filed within the normal 2-business-day window.

Context

• These were straightforward open-market purchases (no option exercises, gifts, or 10b5-1 plan noted). Purchases by a CEO can be read by some investors as a signal of confidence, but filings alone do not reveal motive. The trust ownership and Dr. Miller’s shared control over trust shares are disclosed in the footnote.